DAWN Research and Charts

DAWN - Day One Biopharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-01-28 (Delayed quote data 2025-01-06)

Last 12.20	Change ⇓ -0.39 (-3.10%)	Volume 962,744
	Open 12.64	High 12.64	Low 12.18

8EMA (Daily) 12.59	40EMA (Daily) 13.25	50EMA (Daily) 13.39	STO (Daily) 35.176	MACD Hist (Daily) 0.000
8EMA (Weekly) 13.017	40EMA (Weekly) 13.95	50EMA (Weekly) 14.04	STO (Weekly) 10.188	MACD Hist (Weekly) -0.433


Company Profile
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.